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Introduction
Gleason score (GS) 6 prostate cancer (PCa) represents a broad disease spectrum, with optimum treatment varying widely from active surveillance (AS) to immediate curative therapy [1] . Characterizing the true biological aggressiveness of GS6 tumours has proven difficult [2] , leading to the potential for both overtreatment and undertreatment [3] [4] [5] . This is especially true for the subset of GS6 tumours that meet the clinical qualifications for National Comprehensive Cancer Network (NCCN) low-risk disease or Cancer of the Prostate Risk Assessment (CAPRA) low-risk disease, as the available clinical variables add little to no additional prognostic discrimination within this narrowly defined patient subset. Indeed, some men, even those with high-volume GS6 cancers, may be reasonable candidates for AS based on their underlying tumour biology, but ultimately undergo definitive therapy [6] . Conversely, some men with clinical and pathological findings consistent with low-risk cancer in fact harbour a more aggressive phenotype [7, 8] . While likely to depend on the intensity of monitoring, the randomized ProtecT trial showed that the use of AS in some patients could increase the risk of adverse clinical outcomes over the long term [9] .
Tissue-based genomic tests, such as the cell cycle progression (CCP) score, can help decrease prognostic uncertainty and improve risk stratification of GS6 PCa [6] . Previous studies have shown that CCP scores measured in prostate biopsy and radical prostatectomy (RP) specimens were predictive of several clinical outcomes [10] [11] [12] [13] [14] [15] ; however, it is currently unclear whether the CCP score improves clinical risk stratification within NCCN low-risk PCa or GS6 tumours more generally. The aim of the present study, therefore, was to determine the prognostic utility of the CCP score derived from prostate biopsies of men with low-risk PCa who underwent RP.
Patients and Methods

Patient Cohort
The study population included men with GS ≤6 PCa who underwent RP at the Martini Clinic (MC), the Durham Veterans Affairs Medical Center (DVA), or Intermountain Healthcare (IH). These populations have been described in a previous report [10] . In brief, the MC cohort included 316 men, randomly selected from a consecutive series of RPs performed between 2005 and 2006. Because original diagnostic biopsies were not available, tissue for analysis was obtained via simulated biopsy in which 0.6-mm tissue cores were sampled from tumour blocks as previously described [10] . The DVA population included 186 men with diagnostic biopsy tissue available who underwent RP for PCa between 1994 and 2005. The third cohort included 151 men with diagnostic biopsy tissue available who underwent RP at IH between 1997 and 2004. Men with histologically confirmed GS ≤6 cancers were identified and included in the analysis.
Cell Cycle Progression Score
The CCP score measures the expression of 31 genes involved in cell cycle progression, which are normalized by the expression of 15 housekeeper genes to provide a robust, reproducible measure of cell proliferation [14] . A boardcertified pathologist at Myriad Genetics identified carcinoma tissue for analysis from formalin-fixed paraffin-embedded biopsy samples. The selected tissue regions were macrodissected, cut into ten 10-lm sections, and deparaffinized. RNA extraction was performed using miRNeasy (Qiagen, Valencia, CA, USA), and gene expression was quantified using TaqMan low-density arrays [14] . All samples were run in triplicate. CCP scores were rejected if >9 CCP genes were missing or if the standard deviation of the triplicate score was >0.5.
Outcome
The primary outcome was biochemical recurrence (BCR) after RP. Individuals were censored at 10 years of follow-up. In the MC cohort, BCR was defined as postoperative PSA >0.2 ng/mL or the initiation of secondary treatment (androgen therapy or radiation) for increasing PSA regardless of PSA value [10] . For the DVA cohort, BCR was defined according to these same criteria, along with the additional criterion of PSA >0.2 ng/mL for two consecutive measurements at least 3 months apart. In the IH cohort, BCR was defined as PSA >0.2 ng/mL in men with a previous PSA nadir of 0 ng/mL.
Statistical Analysis
The demographic and clinical characteristics of the study cohort were assessed. Because NCCN classification is commonly used for clinical risk stratification, analysis was performed in a subset of men meeting NCCN low-risk criteria (T1-T2a and PSA <10 ng/mL) [1] in addition to the overall GS ≤6 population. Freedom from BCR was assessed using the Kaplan-Meier time-to-event approach and the logrank test. CCP scores were divided into low (≤0), intermediate (0.01-1.0) and high (>1.0) risk groups for illustrative purposes, but the continuous CCP score was used in all other statistical analyses. Univariable and multivariable Cox proportional hazards models were used to identify factors associated with BCR (with and without stratifying by study institution). It was determined a priori that the validated CAPRA score would be included in multivariable models to account for conventional clinical and pathological risk factors [16] . To ensure the simulated biopsies (MC cohort) did not unduly influence our results, we repeated the combined analyses using CCP scores generated from only diagnostic biopsies (DVA and IH cohorts). To assess the discriminative ability of the CCP score to predict BCR at 5-and 10-year follow-up in the low-risk cohort, Harrell's Cindex was calculated for three models: CCP score; CAPRA; and CCP score + CAPRA models. Decision-curve analysis was used to compare the utility of these three models for predicting BCR at 5-year follow-up. All statistical analyses were performed using STATA Intercooled v13.0 (College Station, TX, USA) and R statistical package (R Foundation, Vienna, Austria). Institutional review board approval was secured from the Johns Hopkins Medical Institutions (Baltimore, MD).
Results
The final study cohort included 236 patients with GS ≤6 PCa who had CCP scores and complete clinical and pathological data to calculate CAPRA scores. As shown in Table 1 , the median (interquartile range [IQR]) patient age was 61.4 (57.0-65.7) years and median (IQR) PSA was 5.7 (4.4-7.8) ng/mL. Each study institution contributed approximately onethird of the final cohort. The majority of the men had lowrisk cancer based on CAPRA score (74.8%) and NCCN criteria (79.7%). The median (IQR) CCP score was À0.15 (À0.7 to À0.4) and 59.3% of the population had a CCP score ≤0. In total, 56 men experienced BCR at a median (IQR) of 24.5 (7-59) months from surgery. The median (IQR) overall follow-up was 81 (61-120) months in men who did not experience BCR.
Biochemical recurrence
Kaplan-Meier analysis of freedom from BCR is shown in Fig. 1 . The 5-year BCR-free survival rates in the low, intermediate and high CCP score groups were 89.2%, 80.4% and 64.7%, respectively, in the NCCN low-risk cohort (P = 0.027) and 85.9%, 79.1% and 63.1%, respectively, in the overall cohort (P = 0.041; Table 2 ).
Cox Proportional Hazards Models
Univariable and multivariable Cox proportional hazards models for BCR in the NCCN low-risk subset and the overall cohort are shown in Table 3 . Among men with NCCN low-risk PCa, CCP score was associated with BCR in univariable analysis (hazard ratio [HR] per score unit 1.77, 95% CI 1.23, 2.56; P = 0.002). In multivariable analysis, including CAPRA score, the CCP score was found to have a similar association with BCR (HR 1.77, 95% CI 1.21-2.58; P = 0.003). In the overall cohort, the CCP score was also associated with BCR in both univariable (HR per score unit 1.46, 95% CI 1.06-2.01; P = 0.02) and multivariable analysis (HR 1.41, 95% CI 1.02-1.96; P = 0.039).
The Cox proportional hazard analyses were repeated after stratifying the patient cohort by study institution. In general, similar HRs were obtained after adjusting for CAPRA (HR per score unit 1.57 in men with NCCN low-risk PCa and HR per score unit 1.38 in the overall cohort), although the HR in the overall cohort did not meet conventional levels of statistical significance (P = 0.056; Table S1 ).
Sensitivity Analyses of Men who Underwent Diagnostic Biopsy
In the overall cohort, after exclusion of the cases with simulated biopsy (MC study institution), the magnitude of the CCP HR for BCR changed marginally on both univariable (HR 1.44, 95% CI 1.03-2.02; P = 0.035) and multivariable analysis (HR 1.43, 95% CI 1.01-2.01; P = 0.043), with both HRs meeting statistical significance (Table S2 ). In the NCCN low-risk cohort, the CCP score HR changed marginally on both univariable (HR 1.51, 95% CI 1.04-2.21; P = 0.032) and multivariable analysis (HR 1.59, 95% CI 1.07-2.36; P = 0.021), with lower levels of significance, as would be expected with the decrease in sample size (Table S2) .
Discriminative Ability and Decision-Curve Analysis
The addition of the CCP score to the CAPRA score model increased the C-index by 0.105 and 0.108 at 5-and 10-year follow-up, respectively (Table 4) . Similarly, the decision-curve analysis showed the CCP score + CAPRA model had a higher net positive benefit across a wider range of threshold probabilities than the model with only the CAPRA score (Fig. 2) .
Discussion
The spectrum of favourable-risk PCa includes tumours categorized by the NCCN as very-low-and low-risk [1] . While AS is widely accepted as a primary management CCP 0.01-1 CCP >1 Fig. 1 Biochemical recurrence-free survival stratified by cell cycle progression (CCP) score category in (A) the overall cohort (n = 236) and (B) the NCCN low-risk cohort (n = 188). American race [17, 18] . Furthermore, low-risk cancers represent a wide spectrum of biological aggressiveness, ranging from truly indolent to potentially lethal disease [7, 8, 19] . As current methodologies fail to consistently distinguish among these phenotypes with similar clinical characteristics [20, 21] , there is a significant need for diagnostic tools to improve clinical risk stratification and better identify appropriate treatment strategies for individual patients [19] . In the present study, we assessed the association of CCP score with BCR after RP in men with NCCN low-risk PCa, and more generally, in GS6 PCa. Among the subset of men meeting NCCN low-risk criteria, the CCP score was a robust and independent predictor of BCR in the multivariable model adjusted for conventional clinical and pathological risk factors using the CAPRA score.
These findings provide further support that the CCP score informs of risk that is not accounted for by conventional variables such as serum PSA and cancer extent on diagnostic biopsy. Considering specifically the NCCN low-risk population, in which all men have similar clinical and pathological findings, a 1-point increase in CCP score was associated with a nearly 80% increase in the risk of BCR (HR per score unit 1.77, 95% CI 1.21-2.58; P = 0.003) while the CAPRA score (HR per score unit 1.02, 95% CI 0.65-1.60; P = 0.9) was not associated with BCR. Additionally, the estimated HR (effect size) for the association of CCP score with BCR was reasonably similar in the overall GS ≤6 cohort (HR per score unit 1.41, 95% CI 1.02-1.96; P = 0.039) and the low-risk cohort. Altogether, these data further validate the use of CCP score for risk stratification of men with low-grade cancers, and suggest that CCP score may be very useful in the population of men who meet conventional NCCN low-risk criteria.
Previous studies performed in more diverse patient populations have demonstrated a similar association of CCP score with various long-term outcomes, including metastatic disease and PCa death [10] [11] [12] [13] [14] [15] . For example, in a heterogeneous cohort of patients with low-(32%) to intermediate-/high-risk (68%) PCa, Bishoff et al. [10] demonstrated a nearly 50% increase in the risk of BCR after RP (HR 1.47, 95% CI 1.23-1.76; P < 0.001) and a more than fourfold increase in the risk of metastatic disease (HR 4.19, 95% CI 2.08-8.45; P < 0.001) with a one-point increase in biopsy-derived CCP score. Similarly, Cooperberg et al. [11] observed a 70% increase in the risk of BCR (HR 1.7, 95% CI 1.3-2.3; P < 0.001) with a 1-point increase in CCP scores from the dominant tumour focus in RP specimens in a cohort of men with low-risk (67%), intermediate-risk (28%), and high-risk (6%) disease based on CAPRA-S scores [11] . A recent meta-analysis including these studies and three others found that the risk of BCR increased by >60% (pooled HR 1.63 95% CI 1.44-1.85; P < 0.001) and risk of PCa death more than doubled (pooled HR 2.08, 95% CI 1.38-3.16; P = 0.001) with a 1-point increase in CCP score [22] .
Based on the hypothesis that the CCP score could be most clinically useful in men with favourable-risk disease, the present study focused on a population of men with NCCN low-risk disease. In this regard, our findings build on those of Cooperberg et al. [11] , who assessed the CCP score from RP tissue in a subgroup of men with low-risk PCa defined using CAPRA-S scores of ≤ 2. In that population, the authors found that the CCP score could effectively sub-stratify patients into different risk groups for BCR after RP (P = 0.003). Furthermore, on univariable analysis the risk of BCR after RP more than doubled (HR 2.3, 95% CI 1.4-3.7), with a 1-point increase in CCP score. Encouragingly, we observed a similar association of CCP score with BCR in a low-risk population as designated by NCCN criteria, specifically after adjustment for CAPRA score. The ability of the CCP score to improve clinical risk stratification of patients at low risk was further supported by the C-index and decision-curve analyses, which demonstrated a substantial incremental benefit with the addition of CCP score to the CAPRA score in order to predict BCR at 5-and 10-year follow-up.
Taken together, these studies support the use of the CCP score to improve clinical risk stratification in NCCN lowrisk men both at biopsy and after RP. In the present study, over one-third of low-risk patients had CCP scores >0, putting them at an appreciable risk of BCR after RP. Based on previous studies, these men likely harbour tumours with more aggressive underlying biology, and as such may not be as well suited for conservative management as their clinical and pathological features suggest [10] [11] [12] [13] [14] [15] . Nevertheless, it is important for healthcare providers to remember that the results of genetic tests, such as the CCP score, must be used in conjunction with other clinical information and patient demographics in order to create a stronger understanding of the overall clinical picture and underlying disease aggressiveness. As always, educating patients about the results of the CCP score is especially important, as there is a continued need for shared decisionmaking with patients to reach decisions regarding PCa treatment.
The present study has some limitations that should be noted. One of the three cohorts in this study used a simulated biopsy instead of a diagnostic biopsy. Importantly, however, our findings were similar in the sensitivity analysis that excluded the simulated biopsy cohort. Additionally, this analysis was based on CCP scores obtained from simulated and diagnostic biopsies and did not consider RP pathology; however, the use of biopsy tissue is more relevant to understanding the clinical utility of the CCP score because it relates to initial treatment decision-making for men with lowrisk PCa. Furthermore, the endpoint of this study was BCR after RP, which is considered a proxy for a biologically aggressive disease phenotype. In these men with favourable risk, the outcome of BCR after RP may not necessarily equate 812 © 2017 The Authors BJU International © 2017 BJU International to adverse outcomes after choosing AS; however, it is likely that the CCP score provides information to men with favourable risk who are faced with difficult treatment decisions, such as whether to enroll in AS or undergo immediate treatment. Based on these findings, future prospective studies are warranted to investigate the potential utility of CCP scores in predicting adverse outcomes among men undergoing AS. Moreover, the definition of BCR was slightly different in each cohort. Nonetheless, the relationships observed were consistent in men with low-risk PCa treated at three institutions, increasing the generalizability of our findings.
In conclusion, the biopsy-derived CCP score improved the clinical risk stratification of men with NCCN low-risk PCa. It is reasonable to use the CCP score in such patients to better assess the appropriateness of AS and better guide treatment selection.
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Additional Supporting Information may be found in the online version of this article: Table S1 . Univariable and multivariable Cox proportional hazards models to identify predictors of BCR in the overall and low-risk cohorts with all analyses stratified by study institution. Table S2 . Univariable and multivariable Cox proportional hazards models to identify predictors of BCR in the overall and low-risk cohorts excluding the MC samples with all analyses stratified by study institution.
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